These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 21048934

  • 21. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
    Tural C, Galeras JA, Planas R, Coll S, Sirera G, Giménez D, Salas A, Rey-Joly C, Cirera I, Márquez C, Tor J, Videla S, García-Retortillo M, Clotet B, Solà R.
    Antivir Ther; 2008; 13(8):1047-55. PubMed ID: 19195330
    [Abstract] [Full Text] [Related]

  • 22. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M, Furusyo N, Ogawa E, Mitsumoto F, Hiramine S, Ikezaki H, Takayama K, Shimizu M, Toyoda K, Kainuma M, Hayashi J.
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [Abstract] [Full Text] [Related]

  • 23. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy.
    Dayyeh BK, Gupta N, Sherman KE, de Bakker PI, Chung RT, Aids Clinical Trials Group A5178 Study Team.
    PLoS One; 2011 May; 6(10):e25753. PubMed ID: 22003405
    [Abstract] [Full Text] [Related]

  • 24. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
    Maida I, Martin-Carbonero L, Sotgiu G, Vispo E, Barreiro P, Gonzalez-Lahoz J, Soriano V.
    J Viral Hepat; 2010 Dec; 17(12):866-71. PubMed ID: 20088891
    [Abstract] [Full Text] [Related]

  • 25. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.
    Ridruejo E, Solano A, Marciano S, Galdame O, Adrover R, Cocozzella D, Delettieres D, Martínez A, Gadano A, Mandó OG, Silva MO.
    Ann Hepatol; 2011 Dec; 10(4):452-7. PubMed ID: 21911885
    [Abstract] [Full Text] [Related]

  • 26. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    Ramos B, Núñez M, Rendón A, Berdún MA, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Barreiro P, Romero M, Labarga P, Guardiola JM, Garcia-Samaniego J, Soriano V.
    J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
    [Abstract] [Full Text] [Related]

  • 27. Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.
    Pineda JA, Caruz A, Di Lello FA, Camacho A, Mesa P, Neukam K, Rivero-juárez A, Macías J, Gómez-Mateos J, Rivero A.
    AIDS; 2011 Jul 17; 25(11):1415-20. PubMed ID: 21572301
    [Abstract] [Full Text] [Related]

  • 28. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
    Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, Palomares JC, Mira JA, Martínez A, Roldán C, de la Torre J, Macías J.
    Clin Infect Dis; 2010 Oct 01; 51(7):788-95. PubMed ID: 20804372
    [Abstract] [Full Text] [Related]

  • 29. Relating the outcome of HCV infection and different host SNP polymorphisms in a Majorcan population coinfected with HCV-HIV and treated with pegIFN-RBV.
    Matas M, Picornell A, Cifuentes C, Payeras A, Homar F, González-Candelas F, López-Labrador FX, Moya A, Ramon C, Castro JA.
    Int Microbiol; 2014 Mar 01; 17(1):11-20. PubMed ID: 25296442
    [Abstract] [Full Text] [Related]

  • 30. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E, Barreiro P, Rodriguez-Nóvoa S, Morello J, Labarga P, Martín-Carbonero L, Maida I, García-Gascó P, Soriano V.
    Antivir Ther; 2008 Mar 01; 13(4):511-7. PubMed ID: 18672529
    [Abstract] [Full Text] [Related]

  • 31. Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection.
    Osaki R, Nishimura T, Shioya M, Takeuchi T, Okumura Y, Nakahara T, Bamba S, Nakajo S, Fujiyama Y, Andoh A.
    Mol Med Rep; 2012 Feb 01; 5(2):525-8. PubMed ID: 22052088
    [Abstract] [Full Text] [Related]

  • 32. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P, Maida I, Cattelan AM, Pontali E, Angeli E, Giralda M, Verucchi G, Caputo A, Iannacone C, Puoti M, Carosi G.
    J Womens Health (Larchmt); 2015 Feb 01; 24(2):159-64. PubMed ID: 25682817
    [Abstract] [Full Text] [Related]

  • 33. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.
    Rivero-Juarez A, Lopez-Cortes LF, Camacho A, Caruz A, Torres-Cornejo A, Martinez-Dueñas L, Ruiz-Valderas R, Torre-Cisneros J, Gutierrez-Valencia A, Rivero A.
    AIDS; 2013 Jul 31; 27(12):1941-7. PubMed ID: 23917425
    [Abstract] [Full Text] [Related]

  • 34. IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.
    Zeremski M, Dimova RB, Makeyeva J, Sipley JD, Jacobson IM, Rennert H, Talal AH.
    J Acquir Immune Defic Syndr; 2013 May 01; 63(1):9-16. PubMed ID: 23274935
    [Abstract] [Full Text] [Related]

  • 35. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
    Kovari H, Russmann S, Ledergerber B, Müller D, Rotger M, Velli P, Cavassini M, Ambrosioni J, Bregenzer A, Stöckle M, Bernasconi E, Rauch A, Speck RF, Swiss HIV Cohort Study.
    PLoS One; 2015 May 01; 10(7):e0133879. PubMed ID: 26218843
    [Abstract] [Full Text] [Related]

  • 36. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.
    Grebely J, Hellard M, Applegate T, Petoumenos K, Yeung B, Feld JJ, Rawlinson W, Lloyd AR, George J, Kaldor JM, Dore GJ, Matthews GV, ATAHC Study Group.
    AIDS; 2012 Aug 24; 26(13):1653-61. PubMed ID: 22555168
    [Abstract] [Full Text] [Related]

  • 37. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.
    Rivero-Juárez A, Camacho Espejo A, Perez-Camacho I, Neukam K, Caruz A, Mira JA, Mesa P, García-Lázaro M, Torre-Cisneros J, Pineda JA, Rivero A.
    J Antimicrob Chemother; 2012 Jan 24; 67(1):202-5. PubMed ID: 21990051
    [Abstract] [Full Text] [Related]

  • 38. Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy.
    Takita M, Hagiwara S, Arizumi T, Hayaishi S, Ueda T, Kitai S, Yada N, Inoue T, Minami Y, Chung H, Ueshima K, Sakurai T, Kudo M.
    Digestion; 2011 Jan 24; 84 Suppl 1():56-61. PubMed ID: 22156487
    [Abstract] [Full Text] [Related]

  • 39. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.
    Fernández-Rodríguez A, Rallón N, Berenguer J, Jiménez-Sousa MA, Cosín J, Guzmán-Fulgencio M, Restrepo C, Lopez JC, García-Álvarez M, Miralles P, Soriano V, Benito JM, Resino S.
    AIDS; 2013 Jan 14; 27(2):163-73. PubMed ID: 23135173
    [Abstract] [Full Text] [Related]

  • 40. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Martín-Carbonero L, Puoti M, García-Samaniego J, De Luca A, Losada E, Quinzan G, Bruno R, Mariño A, González M, Núñez M, Soriano V.
    J Viral Hepat; 2008 Oct 14; 15(10):710-5. PubMed ID: 18637070
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.